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Taiwan University Hospital Yun-Lin Branch, Yun-Lin, TaiwanAbstractIsoniazid mono-resistance is the most common ﬁrst-line drug resistance in tuberculosis (TB), but its treatment outcome remains unclear.
From January 2004 to October 2011, 425 (5.1%) of 8414 patients with culture-conﬁrmed pulmonary TB from four hospitals in Taiwan
were identiﬁed as having isoniazid mono-resistant TB. Among them, 395 (92.9%) were included and followed up for 2 years after
complete treatment. Although 328 (83.0%) patients were successfully treated, 67 (17.0%) had unfavourable outcomes, including death in
56 (14.2%) and treatment failure in 11 (2.8%). The treatment success rate was similar in patients with high-level and low-level isoniazid-
resistant TB (82.2% versus 83.4%, p 0.785) and among those taking anti-TB treatment with and without isoniazid (83.1% versus 83.0%,
p 1.000). Patients without rifampicin interruption had lower risk of unfavourable outcome (14.3% versus 37.0%, p <0.001), especially
those with low-level isoniazid resistance (11.5% versus 56.5%, p <0.001). Supplementation with a new-generation ﬂuoroquinolone
improved treatment success (60.0% versus 12.5%, p 0.003). The presence of cavitary lesions was signiﬁcantly associated with a higher
relapse rate (4.1% versus 0.0%, p 0.006) and extended treatment of 7–9, 10–12 and >12 months had less relapse than 6-month
treatment (3.2%, 0%, 3.7% and 25.0%, respectively, p 0.037). Multivariate Cox proportional hazards analysis revealed that co-morbidity
with cancer (hazard ratio, 2.43) and rifampicin interruption (hazard ratio 1.91) were independent factors associated with unfavourable
outcomes. Treatment throughout with rifampicin and extended treatment for cavitary disease are crucial for improving outcomes in
patients with isoniazid mono-resistant TB.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: jywang@ntu.edu.twIntroductionDespite the availability of chemotherapy, tuberculosis (TB),
especially drug-resistant TB, remains one of the most serious
challenges to public health, with an estimated 8.6 million newClinical Microbiology and Infection © 2014 European Society of Ccases and 1.3–1.6 million TB-related deaths in 2012 [1].
Isoniazid is an important ﬁrst-line anti-TB drug because of its
potent early bactericidal activity against rapidly dividing cells [2].
Combined multiple anti-TB drug therapy with isoniazid pre-
vents the selection and emergence of a drug-resistant TB
population. However, resistance to isoniazid is the most com-
mon drug resistance among all of the ﬁrst-line drugs, with an
estimated prevalence of 13% worldwide, including new and re-
treatment cases.[3] Hence, the effect of such resistance on
treatment outcome is of particular interest.
The optimal regimen for treating isoniazid mono-resistant
TB is still unknown. Although studies in the 1970s and 1980sClin Microbiol Infect 2015; 21: 59–68
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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60 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIreport a low rate of treatment failure for patients with isoniazid
mono-resistant TB receiving four or ﬁve drugs in 6-month
regimens [4,5], some recent studies reveal that patients with
isoniazid mono-resistant TB have worse outcomes than those
with drug-susceptible TB [6–9]. To better evaluate the efﬁcacy
of current treatment regimens in patients with isoniazid mono-
resistant TB, this retrospective cohort study compared treat-
ment outcomes of various anti-TB regimens for patients with
isoniazid mono-resistant TB.MethodsPatient selection
This study was conducted in four hospitals in northern, central,
southern and eastern Taiwan. In Taiwan, directly observed
therapy has been implemented nationwide since April 2006.
According to government regulations, all TB patients should be
reported and registered, and are required to submit at least
two sputum samples for both acid-fast smear and mycobacterial
culture on the second and ﬁfth months of treatment. For pa-
tients with culture-positive TB, sputum samples were collected
for mycobacterial culture every month until conversion. Drug
sensitivity test was repeated if there was a positive culture for
Mycobacterium tuberculosis 3 months after the index culture
[10]. Acquired drug resistance was diagnosed if the follow up
M. tuberculosis isolates acquired more drug resistance during
treatment. All patients with culture-conﬁrmed pulmonary TB
from January 2004 to October 2011 were screened by
reviewing the database of mycobacterial laboratories. Those
who were transferred-out within the 2 two months of anti-TB
treatment were excluded. The Institutional Review Boards of
the National Taiwan University Hospital (201205025RIC) and
Chest Hospital (B-ER-102-164) approved the study.
Laboratory study
All sputum samples were decontaminated and liqueﬁed using
NaOH. The smears were examined by Ziehl–Neelsen staining.
Processed samples were inoculated into two types of media: the
BACTEC MGIT (BACTEC Mycobacterium Growth Indicator
Tube, MGIT 960 system; Becton-Dickinson, Franklin Lakes, NJ,
USA) and the Lowenstein–Jensenmedium. Growth on either one
of the two culture media was considered culture-positive. Myco-
bacterial species were identiﬁed using conventional biochemical
testing whereas the susceptibility test was performed using the
indirect proportionmethod [11]. The critical concentrationswere
0.2 μg/mL (low-level) and 1.0 μg/mL (high-level) for isoniazid,
1.0 μg/mL for rifampicin, and 5.0 μg/mL for ethambutol based on
the WHO recommendations [12]. Antibodies to the human im-
munodeﬁciency virus were assayed as tuberculosis registry.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectCourse of anti-TB treatment
In Taiwan, the recommended anti-TB treatment regimen for
newly diagnosed TB is a short-course (6 months) directly
observed regimen, consisting of a daily four-drug combination
(isoniazid, rifampicin, ethambutol and pyrazinamide) for 2
months (initiation phase) followed by daily isoniazid, rifampicin
and ethambutol for an additional 4 months (continuation phase)
[13]. A ﬁve-combination regimenn (i.e. isoniazid, rifampicin,
ethambutol, pyrazinamide and streptomycin) was recom-
mended in cases with previous history of anti-TB treatment for
more than 1 month [13]. The regimens were adjusted by the
primary-care physicians according to adverse drug effects, and
results of drug susceptibility testing.
Data collection
The patients’ medical records were reviewed to obtain data on
associated medical conditions, laboratory ﬁndings, treatment
course, and outcomes. Baseline chest X-rays (CXRs) before
treatment were evaluated by an experienced pulmonologist
who was blinded to the clinical data. Disease extent on baseline
CXR was evaluated as a radiographic score [14]. Brieﬂy, each
lung was divided into three areas and each area was rated on a
four-point scale of 0–3 for the extent of inﬁltration, with a
maximum radiographic score of 18. Higher scores meant
greater extent of disease involvement. The CXRs with radio-
graphic score of 0–6, 7–12, and 13–18 were further deﬁned as
mild, moderate, and severe, respectively.
Outcome of anti-TB treatment was based on the WHO
deﬁnition [15]. Both cured patients and those with completed
treatments were deﬁned as treatment success, whereas failure,
death during treatment and default (loss to follow up for >2
months) were deﬁned as unfavourable outcomes. Relapse
within 2 years after complete treatment was assessed by na-
tional registered database.
Statistical analysis
Categorical variables were compared using the chi-square test
or Fisher’s exact test, where appropriate, and differences in
continuous variables were analysed using the Mann–Whitney U
test. Data were presented as number (%) unless otherwise
noted. Kaplan–Meier survival analyses for disease-free survival
were constructed and subgroups were compared using log-
rank test.
Multivariate analysis with Cox’s proportional hazards model
was used to determine independent variables that predicted
unfavourable outcomes. A variance inﬂation factor was used to
quantify the severity of multi-collinearity and only variables with
p < 0.10 in univariate analysis and a variance inﬂation factor < 4
were included in the multivariate analysis. For treatment regi-
mens, only those with a whole treatment course were chosenious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 59–68
CMI Chien et al. Outcome of INH-resistant tuberculosis 61for multivariate analysis. All of the statistical analyses were
performed using the SPSS version 17 software. Two-sided p
<0.05 was considered statistically signiﬁcant.ResultsThere were 8414 patients with culture-conﬁrmed pulmonary
TB from January 2004 to October 2011. Among them, 425
(5.1%) with isoniazid mono-resistant TB were identiﬁed. Thirty
(7.1%) were excluded for being transferred-out within 2
months of therapy (Fig. 1). The 395 (92.9%) patients who were
included had a median age of 64.0 years, 299 (75.7%) were male
(Table 1) and six (1.5%) were co-infected with human immu-
nodeﬁciency virus. Three hundred and forty-ﬁve patients
(87.3%) were new cases and 201 (50.9%) were smear-positive.
Of the 395 patients, 205 (51.9%) had low-level isoniazid-resis-
tant TB, 174 (44.1%) had high-level isoniazid-resistant TB (re-
sults unavailable in 16 patients). A total of 328 (83.0%) had
treatment success and 67 (17.0%) had unfavourable outcomes,
comprising 11 (2.8%) with treatment failure and 56 (14.2%)
who died. Treatment regimens are described in Table 1.
Throughout the initiation and continuation phase, 290 (73.4%)
and 196 (49.6%) continued using isoniazid, respectively (Fig. 1).
Fifty-nine (14.9%) patients received 6 months of treatment and
treatment was extended to 7–9, 10–12, and > 12 months inFIG. 1. The study proﬁle, including treatment regimens and reasons for
exclusion.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolo128 (32.4%), 92 (23.3%), and 76 (19.2%) patients, respectively
(see Supporting information; Table S1).
Unfavourable outcome
Compared with patients with treatment success (Table 1),
those with unfavourable outcomes were older (70.7 ± 15.7
versus 59.3 ± 19.2 years, p <0.001), more likely to be male
(p 0.010), smokers (p 0.004), more likely to have underlying
malignancy (p < 0.001), and liver cirrhosis (p = 0.019).
By radiography, patients with unfavourable outcomes were also
more likely to have moderate-to-severe disease (p 0.049) and
lower lung ﬁeld involvement (p 0.030). Patients with treatment
success were more likely to receive rifampicin (82.1% versus
95.7%, p <0.001) or ethambutol (74.6% versus 87.2%, p 0.009;
Table 1) continuously during the initiation phase of treatment.
In the continuation phase, they were also more likely to
keep using rifampicin (75.0% versus 91.2%, p 0.010). Table 2
shows the factors associated with mortality and treatment
failure.
Kaplan–Meier analysis revealed that probability of unfav-
ourable outcomes was not signiﬁcantly different between those
with high-level and low-level isoniazid resistant TB (p 0.785)
and between those treated with and without isoniazid (p 1.000;
Figs. 2a and b). Although the Kaplan–Meier curves were visually
separated, continuous use of ethambutol was not signiﬁcantly
associated with less unfavourable outcomes (Figs. 2c and d).
Compared with 46 patients who were unable to tolerate
rifampicin, 349 patients without rifampicin interruption had
lower probabilities of unfavourable outcome (50/349, 14.3%
versus 17/46, 37.0%, p <0.001, Table 1), especially among 205
patients with low-level isoniazid-resistant TB (21/182, 11.5%
versus 13/23, 56.5%, p 0.001) (Fig. 2e). The clinical character-
istics between patients with/without rifampicin interruption
were similar except more patients with rifampicin interruption
had cirrhosis of the liver (Supporting information, Table S2).
Among the 23 patients with low-level isoniazid resistant TB and
rifampicin interruption during treatment, a new ﬂuo-
roquinolone was used in 15 cases and associated with lower
probabilities of unfavourable outcome (6/15, 40.0% versus 7/8,
87.5%; p 0.003, by log-rank test).
Underlying malignancy (hazard ratio (HR): 2.43, 95% conﬁ-
dence interval (CI): 1.32–4.48; p 0.004) and rifampicin inter-
ruption during the treatment period (HR: 1.91, 95% CI
1.07–3.42; p 0.029) were independent factors associated with
unfavourable outcomes (Table 3). After adjusting the different
characteristics between patients with and without rifampicin
interruption (prevalence of cirrhosis of liver and treatment
regimens), rifampicin interruption remained an independent
predictor of unfavourable outcome (HR: 2.44, 95% CI
1.34–4.45; p 0.004).gy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 59–68
TABLE 1. Characteristics of patients with isoniazid mono-resistant tuberculosis
All (n [ 395)
Treatment
success (n [ 328)
Unfavourable
outcomes (n [ 67) p value
Prior treatment of TB 50 (12.7) 36 (11.0) 14 (20.9) 0.026
Age (years) <0.001
<44 79 (20.0) 76 (23.2) 3 (4.5)
45–64 113 (28.6) 95 (29.0) 18 (26.9)
65 203 (51.4) 157 (47.8) 46 (68.6)
Male 299 (75.7) 240 (73.2) 59 (88.1) 0.010
Smoking history 190 (48.1) 147 (44.8) 43 (64.2) 0.004
Co-morbidity
Diabetes mellitus 101 (25.6) 82 (25.0) 19 (28.4) 0.566
Cancer 41 (10.4) 25 (7.6) 16 (23.9) <0.001
Liver cirrhosis 14 (3.5) 8 (2.4) 6 (9.0) 0.019
End-stage renal disease 14 (3.5) 10 (3.0) 4 (6.0) 0.270
Positive AFB smear 201 (50.9) 167 (50.9) 34 (50.7) 0.980
Findings of CXR
Disease extent 0.114
Mild 237 (60.0) 204 (62.2) 33 (49.3)
Moderate 118 (29.9) 94 (28.7) 24 (35.8)
Severe 40 (10.1) 30 (9.1) 10 (14.9)
Lower lung involvement 100 (25.3) 76 (23.2) 24 (35.8) 0.030
Cavitary lesions 110 (27.8) 90 (27.4) 20 (29.9) 0.688
Cavity size 0.791
<4 cm 77 (19.5) 64 (19.5) 13 (19.4)
4 cm 33 (8.4) 26 (7.9) 7 (10.4)
Pleural effusion 42 (10.6) 32 (9.8) 10 (14.9) 0.211
High-level isoniazid resistance 174 (45.9) 143 (43.6) 31 (46.3) 0.751
After 2 months treatment
Smear conversion 334 (84.6) 276 (84.1) 58 (86.6) 0.617
Culture conversion 291 (73.7) 245 (74.7) 46 (68.7) 0.306
Acquired drug resistance 10 (2.5) 5 (1.5) 5 (7.5) 0.015
Drugs throughout the whole treatment course
Isoniazid 219 (55.4) 182 (55.5) 37 (55.2) 0.968
Rifampicin 349 (88.4) 299 (91.2) 50 (74.6) <0.001
Ethambutol 298 (75.4) 255 (77.7) 43 (64.2) 0.019
Pyrazinamide 228 (57.7) 185 (56.4) 43 (64.2) 0.240
Fluoroquinolones 105 (26.6) 88 (26.8) 17 (25.4) 0.806
Drugs throughout the initiation phase
Isoniazid 290 (73.4) 243 (74.1) 47 (70.1) 0.506
Rifampicin 369 (93.4) 314 (95.7) 55 (82.1) <0.001
Ethambutol 336 (85.1) 286 (87.2) 50 (74.6) 0.009
Pyrazinamide 308 (78.0) 258 (78.7) 50 (74.6) 0.468
Streptomycin 33 (8.4) 28 (8.5) 5 (7.5) 0.772
Fluoroquinolones 111 (28.1) 92 (28.0) 19 (28.4) 0.959
Drugs throughout the continuation phasea
Isoniazid 196 (54.4) 182 (55.5) 14 (43.8) 0.264
Rifampicin 323 (89.7) 299 (91.2) 24 (75.0) 0.010
Ethambutol 276 (76.7) 255 (77.7) 21 (65.6) 0.129
Pyrazinamide 203 (56.4) 185 (56.4) 18 (56.3) 1.000
Fluoroquinolones 102 (28.3) 88 (26.8) 14 (43.8) 0.062
Data are presented as n (%).
AFB, acid-fast bacilli; CXR, chest X-ray; TB, tuberculosis.
aExcluding 35 patients who died during the initiation phase, there were 328 and 32 remaining among patients with treatment success and unfavourable outcomes during the
continuation phase, respectively.
62 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIBecause adherence was uncertain before 2006, sensitivity
analysis focusing on the 339 patients who were treated after
directly observed therapy S implementation was performed.
The results showed that the direction and signiﬁcance of the
impact of cancer (HR 2.25, 95% CI 1.17–4.35; p 0.016) and
rifampicin interruption (HR 1.90, 95% CI 1.01–3.56; p 0.046)
on unfavourable outcomes did not change.
Acquired resistance
Ten (2.5%) patients had acquired resistance during anti-TB
treatment, including ﬁve with unfavourable outcomes (new
ethambutol resistance in two, high-level isoniazid resistance in
one, and multi-drug resistance in two) and ﬁve with treatment
success (all had new resistance to streptomycin) (Table 4). The
rate of acquired new drug resistance was signiﬁcantly higher
in patients with unfavourable outcome (7.5% versus 1.5%,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectp 0.019), smear-positive TB (4.5% versus 0.5%, p 0.020),
moderate-to-severe disease on CXR (5.1% versus 0.8%,
p 0.017), cavitary lesions on CXR (8.2% vs. 0.4%, p<0.001), and
treatment with streptomycin (15.2% vs. 1.4%, p=0.001).
Relapse
Four patients (1.2% of 339 survivors) had relapse within the
2-year follow up. Four of the 97 patients with cavitary lesions
on CXR (4.1%) and none (0.0%) of the 242 patients without
cavitary lesion had TB relapse (p 0.006). Among those with
pulmonary cavitation, survivors with a 6-month treatment
regimen had a higher rate of relapse (2/8, 25.0%) during the
2-year follow up than those treated for 7–9 months (1/31,
3.2%), 10–12 months (0/31, 0%), and >12 months (1/27, 3.7%;
p = 0.037). The relapse rates were similar between patients
with (3/47, 6.4%) and without high-level isoniazid resistanceious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 59–68
TABLE 2. Factors associated with different clinical outcomes among patients with isoniazid mono-resistant tuberculosis
Subjects at risk, n
Smear-positive after
2-month treatment
Culture-positive after
2-month treatment Death during treatment Treatment failure Relapsea
n (%) p value n (%) p value n (%) p value n (%) p value n (%) p value
Prior treatment of TB
No 345 55 (15.9) 0.471 90 (26.1) 0.774 43 (12.5) 0.010 10 (2.9) 1.000 4 (1.3) 1.000
Yes 50 6 (12.0) 14 (28.0) 13 (26.0) 1 (2.0) 0 (0.0)
Age (years)
<44 79 8 (10.1) 0.050 19 (24.1) 0.287 2 (2.5) <0.001 1 (1.3) 0.005 2 (2.6) 0.100
45–64 113 25 (22.1) 36 (31.9) 10 (8.8) 8 (7.1) 2 (1.9)
65 203 28 (13.8) 49 (24.1) 44 (21.7) 2 (1.0) 0 (0.0)
Gender
Female 96 9 (9.4) 0.059 17 (17.7) 0.028 7 (7.3) 0.028 1 (1.0) 0.309 1 (1.1) 1.000
Male 299 52 (17.4) 87 (29.1) 49 (16.4) 10 (3.3) 3 (1.2)
Smoking history
Never 205 21 (10.2) 0.003 43 (21.0) 0.012 21 (10.2) 0.020 3 (1.5) 0.128 2 (1.1) 1.000
Yes 190 40 (21.1) 61 (32.1) 35 (18.4) 8 (4.2) 2 (1.3)
Diabetes mellitus
No 294 33 (11.2) <0.001 68 (23.1) 0.014 44 (15.0) 0.443 4 (1.4) 0.008 4 (1.6) 0.576
Yes 101 28 (27.7) 36 (35.6) 12 (11.9) 7 (6.9) 0 (0.0)
Cancer
No 354 56 (15.8) 0.653 97 (27.4) 0.191 40 (11.3) <0.001 11 (3.1) 0.614 4 (1.3) 1.000
Yes 41 5 (12.2) 7 (17.1) 16 (39.0) 0 (0.0) 0 (0.0)
Liver cirrhosis
No 381 60 (15.7) 0.705 101 (26.5) 1.000 50 (13.1) 0.008 11 (2.9) 1.000 4 (1.2) 1.000
Yes 14 1 (7.1) 3 (21.4) 6 (42.9) 0 (0.0) 0 (0.0)
End-stage renal disease
No 381 59 (15.5) 1.000 100 (26.2) 0.767 51 (13.4) 0.035 11 (2.9) 1.000 4 (1.2) 1.000
Yes 14 2 (14.3) 4 (28.6) 5 (35.7) 0 (0.0) 0 (0.0)
Initial smear-positive
No 194 5 (2.6) <0.001 23 (11.9) <0.001 31 (16.0) 0.313 2 (1.0) 0.062 1 (0.6) 0.624
Yes 201 56 (27.9) 81 (40.3) 25 (12.4) 9 (4.5) 3 (1.7)
Disease extent on CXR
Mild 237 24 (10.1) <0.001 51 (21.5) 0.016 31 (13.1) 0.508 2 (0.8) 0.015 1 (0.5) 0.125
Moderate 118 23 (19.5) 37 (31.4) 17 (14.4) 7 (5.9) 2 (2.0)
Severe 40 14 (35.0) 16 (40.0) 8 (20.0) 2 (5.0) 1 (3.1)
Lower lung involved
No 295 33 (11.2) <0.001 69 (23.4) 0.023 37 (12.5) 0.110 6 (2.0) 0.155 2 (0.8) 0.242
Yes 100 28 (28.0) 35 (35.0) 19 (19.0) 5 (5.0) 2 (2.5)
Cavitary lesions on CXR
No 285 30 (10.5) <0.001 60 (21.1) <0.001 43 (15.1) 0.404 4 (1.4) 0.013 0 (0.0) 0.006
Yes 110 31 (28.2) 44 (40.0) 13 (11.8) 7 (6.4) 4 (4.1)
Pleural effusion
No 353 54 (15.3) 0.816 92 (26.1) 0.727 47 (13.3) 0.162 10 (2.8) 1.000 3 (1.0) 0.337
Yes 42 7 (16.7) 12 (28.6) 9 (21.4) 1 (2.4) 1 (3.0)
High-level Isoniazid resistance
No 205 31 (15.1) 0.915 57 (27.8) 0.765 33 (16.1) 0.264 1 (0.5) 0.003 1 (0.6) 0.346
Yes 174 27 (15.5) 46 (26.4) 21 (12.1) 10 (5.7) 3 (2.0)
Drugs throughout the initiation phase
Isoniazid
No 105 9 (8.6) 0.023 21 (20.0) 0.086 19 (18.1) 0.179 1 (1.0) 0.301 0 (0.0) 0.576
Yes 290 52 (17.9) 83 (28.6) 37 (12.8) 10 (3.4) 4 (1.6)
Rifampicin
No 26 3 (11.5) 0.780 9 (34.6) 0.321 12 (46.2) <0.001 0 (0.0) 1.000 0 (0.0) 1.000
Yes 369 58 (15.7) 95 (25.7) 44 (11.9) 11 (3.0) 4 (1.2)
Ethambutol
No 59 7 (11.9) 0.558 13 (22.0) 0.417 15 (25.4) 0.007 2 (3.4) 0.672 1 (2.3) 0.428
Yes 336 54 (16.1) 91 (27.1) 41 (12.2) 9 (2.7) 3 (1.0)
Pyrazinamide
No 87 20 (23.0) 0.027 29 (33.3) 0.093 15 (17.2) 0.353 2 (2.3) 1.000 0 (0.0) 0.582
Yes 308 41 (13.3) 75 (24.4) 41 (13.3) 9 (2.9) 4 (1.5)
Streptomycin
No 362 47 (13.0) <0.001 90 (24.9) 0.038 52 (14.4) 1.000 10 (2.8) 1.000 4 (1.3) 1.000
Yes 33 14 (42.4) 14 (42.4) 4 (12.1) 1 (3.0) 0 (0.0)
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect(1/44, 2.3%, p 0.617). The relapse rate among patients receiving
rifampicin throughout the treatment course (4/91, 4.4%) was
also similar to those without rifampicin treatment (0/30, 0.0%; p
1.000).DiscussionWe found that the treatment success rate of patients with
isoniazid mono-resistant TB was similar in patients with high-
level and low-level isoniazid-resistant TB and among those
taking anti-TB treatment with and without isoniazid. More
importantly, patients without rifampicin interruption had less
unfavourable outcomes, especially those with low-level isoni-
azid resistance. Patients with cavitary lesions on CXR had a
higher relapse rate if treated on 6-month regimens.
Treatment practices for isoniazid mono-resistant TB vary
between physicians, because there are no randomized trials
focusing on this speciﬁc population and treatment recommen-
dations are mainly based on expert opinions [6,16–18]. Patients
with high-level isoniazid resistance were considered to have
worse outcomes than those with low-level isoniazid resistance,
especially when isoniazid was used [18]. Hence, the Clinical and
Laboratory Standards Institute suggests testing at two concen-
trations of isoniazid, because patients with low-level isoniazid
resistance may beneﬁt from continuing therapy with isoniazid
[19]. However, several studies have shown that a four-drug 6-
month short-course therapy with/without isoniazid can be
similarly efﬁcacious in treating isoniazid-resistant TB
[2,4,5,20–22]. The present study also revealed that regimens
with/without isoniazid have similar treatment success rates not
only among patients with low-level isoniazid-resistant TB but
also among those with high-level resistance. The daily isoniazid
dosage used in this study was 5 mg/kg body weight. No one
received high-dose isoniazid regimens (16–18 mg/kg body
weight), which had been shown to improve sputum conversion
and chest radiography in patients with multi-drug resistant TB
[23,24].
Isoniazid and rifampicin are the two most powerful anti-
tuberculosis drugs that shorten the duration of treatment and
reduce relapse rate [15]. If rifampicin cannot be used in patients
with isoniazid-resistant TB, then the treatment regimen will be
less effective and treatment for 12–18 months may be neces-
sary [20]. The prolonged treatment will be associated with a
worse adherence, leading to a higher recurrence rate and
emergence of resistant strains [15]. Compared with patients
who took rifampicin throughout the treatment period, those
who were unable to tolerate rifampicin had signiﬁcantly lower
treatment success (63.0% versus 85.7%, p <0.001), especially
among patients with low-level isoniazid-resistant TB (43.5%ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 59–68
FIG. 2. Kaplan–Meier plots and log-
rank test for probability of unfav-
ourable outcomes, according to
treatment with or without isoniazid
(a, b), ethambutol (c, d), rifampicin
(e, f) and a new-generation ﬂuo-
roquinolone (g, h) throughout the
treatment process, stratiﬁed by low-
level (n = 174) and high-level
(n = 205) isoniazid resistance.
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TABLE 3. Factors predicting unfavourable outcomes among
patients with isoniazid mono-resistant tuberculosis
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Prior TB treatment 1.92 1.06–3.46 0.031 1.50 0.81–2.77 0.194
Age 65 years 2.26 1.35–3.79 0.002 1.64 0.95–2.83 0.078
Male 2.54 1.21–5.32 0.013 1.88 0.82–4.27 0.134
Smoker 1.95 1.19–3.22 0.009 1.46 0.84–2.54 0.183
Cancer 3.55 2.02–6.24 0.000 2.43 1.32–4.48 0.004
Cirrhosis of liver 3.30 1.42–7.66 0.005 2.26 0.90–5.70 0.084
Lower lung
involvement
1.68 1.02–2.77 0.042 1.58 0.94–2.64 0.082
Rifampicin
interruption
2.38 1.35–4.17 0.003 1.91 1.07–3.42 0.029
Ethambutol
interruption
1.75 1.06–2.89 0.028 1.44 0.85–2.42 0.176
Abbreviations: CI, conﬁdence interval; CXR, chest X-ray; HR, hazard ratio; TB,
tuberculosis.
66 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIversus 88.5%, p <0.001) (Fig. 2) but not among those with high-
level isoniazid-resistant TB. Although patients with rifampicin
interruption were prone to have unfavourable outcomes,
previous studies found that M. tuberculosis strains with the katG
mutation, which conferred high-level isoniazid resistance, had
decreased virulence [25–27] and might contribute to better
outcomes in patients infected with high-level isoniazid-resistant
M. tuberculosis strains even without rifampicin treatment.
Growing evidence suggests that newer ﬂuoroquinolones
such as moxiﬂoxacin and levoﬂoxacin may be as efﬁcacious as
isoniazid against susceptible TB [28]. The WHO guidelines also
suggest that adding a newer ﬂuoroquinolone may strengthen
the regimen among patients with extremely drug-resistant
disease [20]. This study showed that supplementation with a
new ﬂuoroquinolone could improve treatment outcomes in
patients who were unable to continuously use rifampicin.
However, this ﬁnding did not reach statistical signiﬁcance,
possibly because of the small sample size. The higher death rate
among patients treated with ﬂuoroquinolone in the continua-
tion phase may be due to more severe disease condition of
patients for whom the physician might tend to add on drugs, or
just due to random error because of the small number of cases.
Further prospective studies on the efﬁcacy of alternative regi-
mens for such patients are warranted.
Previous clinical trials have shown that a 9-month treatment
regimen (i.e. rifampicin, ethambutol and pyrazinamide) has
fewer cases of relapse than a 6-month regimen among patients
with isoniazid-resistant TB [20,21]. Among patients with cavi-
tation on CXR, the 6-month treatment regimens also had a
higher relapse rate than regimens with extended duration
(25.0% versus 2.2%, p 0.033). The presence of cavitary lesions
on CXR was associated with a high rate of acquired new drug
resistance, consistent with the concept that patients with
cavitary lesions have greater extent of disease and higherClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 59–68
CMI Chien et al. Outcome of INH-resistant tuberculosis 67burden of acid-fast bacilli compared with patients without
cavitary lesions [29].
This study had a number of limitations. First, although TB
treatment guidelines were well-established and implemented in
clinical practice in Taiwan, the anti-TB regimens in this study
were heterogeneous due to the retrospective design. Second,
there was no drug-susceptible TB arm. Although the recently
reported treatment success rate of all TB cases in Taiwan was
similar to the ﬁndings here, there were also different de-
mographic conditions and underlying disease severity. Third,
the mutation status of resistant strains was not checked and the
hypothesis that isoniazid-resistance-conferring mutations may
be associated with treatment outcome warrants further study.
Fourth, because directly observed therapy has been imple-
mented since 2006 in Taiwan, the adherence was uncertain in
patients before 2006.
In conclusion, among patients with isoniazid mono-resistant
TB, those taking rifampicin throughout their treatment period
were signiﬁcantly associated with better treatment success.
Supplementation with newer ﬂuoroquinolones might help to
improve treatment success in patients unable to tolerate
rifampicin throughout their treatment. Patients with cavitary
lesions on CXR had a higher relapse rate if treated with 6-
month regimens. Early detection of isoniazid resistance and
regimen tailoring are crucial for achieving improved outcomes.Transparency declarationsNone to declare.
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